Guidelines for the Management of Prostate Cancer
Guidelines for the Management of Prostate Cancer

Full Version
Guidelines For The Management of Prostate Cancer

Objective:
This guideline reviews the overall management (from initial presentation and diagnosis through referral, treatment and follow up) of prostate cancer in Nova Scotia. This guideline was written for an audience of general practitioners and medical students, not necessarily prostate cancer specialists. As such, it is a synthesis of knowledge and evidence, and reflects the practice policies of the Genitourinary Cancer Site Team in Nova Scotia (see Appendix I). A simplified discussion with flowcharts (practice pathways) will summarize the written contents.

Patients, family members and other non-health professionals are encouraged to review materials written specifically for them. The Canadian Cancer Society Information Service (1-888-939-3333 or www.cancer.ca) is one source for this type of information.

Preamble Note:
Practice guidelines are intended to assist health care professionals with decisions throughout the spectrum of the cancer experience. This guideline is intended to assist health care professionals to care for patients with prostate cancer.

Guidelines should never replace specific decisions for individual patients, and do not substitute for the shared decisions between any patient and doctor (or other health professional) which are unique to each circumstance. Guidelines do provide evidence-based background information, consensus-based recommendations for similar problems, and a context for each individual decision.

This guideline will be reviewed in three years from publication date or earlier if important new evidence becomes available. Current versions of this guideline will be available on the Cancer Care Nova Scotia website (www.cancercare.ns.ca).

Comment on Clinical Research:
An important component of treatment decision-making for any patient is the potential for enrollment in relevant clinical research. The Genitourinary Cancer Site Team is committed to advancing patient care, through participation in clinical trials and other clinical research projects. At any point in time, there may be a clinical trial or other clinical research opportunity related to any component of this guideline. As specific trials or clinical research projects become available, eligible patients may be offered the opportunity to enroll in the relevant trial or research project. Every effort will be made to accommodate patients for clinical research participation, but there will be eligibility restrictions for each trial. Patients are encouraged to discuss clinical trials opportunities with their cancer specialist. Other researchers may also contact patients to offer participation in relevant trials. Current clinical trials are listed on the Cancer Care Nova Scotia website (www.cancercare.ns.ca).

Acknowledgements:
This guideline was written by a collaborative effort of the Genitourinary Cancer Site Team, and was sponsored by Cancer Care Nova Scotia. Portions of this practice guideline have been adapted from guidelines prepared by the British Columbia Cancer Agency and by the...
Guidelines for the Management of Prostate Cancer

Contents:

<table>
<thead>
<tr>
<th>Part</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Part 1</td>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Part 2</td>
<td>Histology &amp; Pathology</td>
<td>4</td>
</tr>
<tr>
<td>Part 3</td>
<td>Diagnosis and Staging</td>
<td>7</td>
</tr>
<tr>
<td>Part 4</td>
<td>Referral Information for the New Patient Visit</td>
<td>10</td>
</tr>
<tr>
<td>Part 5</td>
<td>Treatment of Prostate Cancer</td>
<td>11</td>
</tr>
<tr>
<td>Part 6</td>
<td>Follow-up</td>
<td>18</td>
</tr>
<tr>
<td>Part 7</td>
<td>Supportive Care Issues</td>
<td>19</td>
</tr>
<tr>
<td>Part 8</td>
<td>Practice Pathways</td>
<td>23</td>
</tr>
</tbody>
</table>

Guideline Approvals:

- Genitourinary Cancer Site Team-
  - Initial date approved- 12 September 2005
  - Revision with Community Reviewer Input- 23 January 2006
  - Cancer Care Nova Scotia, Commissioner- 15 February 2006

Recommended citation:

© Crown copyright, Province of Nova Scotia, 2006. May be reprinted with permission from Cancer Care Nova Scotia (1-866-599-2263).
1.1 Epidemiology
In males, prostate cancer is the most common non-cutaneous cancer diagnosed, and the second most common cause of cancer death. Age specific incidence\(^1\) of prostate cancer increased steeply in men over the age of 60 (Figure 1). Age-standardized incidence\(^1\) increased dramatically in the early 1990’s, most likely due to improved detection through the use of the Prostate Specific Antigen (PSA) test (Figure 2). Age-standardized mortality\(^1\), however, has not changed significantly over the same time period of reporting (Figure 3).

Survival rates of men with prostate cancer\(^1\) are substantially better than the other two leading cancers in men, lung cancer and colorectal cancer (Figure 4). The overall five year survival rate for prostate cancer patients in Nova Scotia was 93%. Survival for prostate cancer patients\(^1\) was dependant on the stage of the cancer at diagnosis, ranging from 99% five-year survival for local malignancies to 27% for patients with distant metastases (Figure 5). Fortunately, over half of the patients (53%) were diagnosed with local disease.
Figure 2. Trends in age-standardized incidence rates for common tumor sites, males, Nova Scotia 1971-1999.

**MALES**

Age-standardized incidence rates per 100,000 average annual 1995-99

<table>
<thead>
<tr>
<th>Year</th>
<th>1981</th>
<th>1983</th>
<th>1985</th>
<th>1987</th>
<th>1989</th>
<th>1991</th>
<th>1993</th>
<th>1995</th>
<th>1997</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
<td>300</td>
</tr>
<tr>
<td>Colorectal</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
<td>300</td>
</tr>
<tr>
<td>Lung</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
<td>300</td>
</tr>
</tbody>
</table>

Figure 3. Trends in age-standardized mortality rates for common tumor sites, males, Nova Scotia 1971-1999.

**MALES**

Age-standardized mortality rates per 100,000 average annual 1995-99

<table>
<thead>
<tr>
<th>Year</th>
<th>1981</th>
<th>1983</th>
<th>1985</th>
<th>1987</th>
<th>1989</th>
<th>1991</th>
<th>1993</th>
<th>1995</th>
<th>1997</th>
<th>1999</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
<td>300</td>
</tr>
<tr>
<td>Colorectal</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
<td>300</td>
</tr>
<tr>
<td>Lung</td>
<td>30</td>
<td>60</td>
<td>90</td>
<td>120</td>
<td>150</td>
<td>180</td>
<td>210</td>
<td>240</td>
<td>270</td>
<td>300</td>
</tr>
</tbody>
</table>

Figure 4. Five-year relative survival for common tumor sites, males, Nova Scotia 1992-1996.

The total number of cases (N) retained for analysis appears in parenthesis and a 95% confidence interval (-----) is presented for each estimate.

**MALES**

Relative Survival (%)

<table>
<thead>
<tr>
<th>Time since Diagnosis (Years)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate (N = 2,507)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Colorectal (N = 1,257)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Lung (N = 1,834)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>

Figure 5. Prostate cancer survival by extent of disease, males, Nova Scotia 1992-1996.

The total number of cases (N) retained for analysis appears in parenthesis and a 95% confidence interval (-----) is presented for each estimate.

**MALES**

Relative Survival (%)

<table>
<thead>
<tr>
<th>Time since Diagnosis (Years)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostate</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Regional (N = 57)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Distant (N = 143)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Local (N = 1,331)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Unknown (N = 976)</td>
<td>100</td>
<td>80</td>
<td>60</td>
<td>40</td>
<td>20</td>
<td>0</td>
</tr>
</tbody>
</table>
1.2 Risk Factors
The lifetime risk of developing prostate cancer is approximately 10% and the risk of cancer related mortality is 3%. Risk of prostate cancer is higher in males with a first degree relative with prostate cancer.

1.3. Presentation
Patients may present with an elevated PSA without symptoms, with an asymptomatic prostate abnormality on digital rectal examination (DRE), or with lower urinary tract symptoms. Patients with metastatic disease or locally advanced disease may present with other symptoms referable to the sites of disease involvement (i.e. bone pain, visceral or lymphatic obstruction).

1.4. Screening
See appendix II (CCNS – Prostate Screening Position Statement)

1.4.1 Prostate Specific Antigen (PSA)
Reference Ranges:
Normal values for PSA increase with age, as follows:
40-49 yrs < 2.5 ng/mL
50-59 yrs < 3.5 ng/mL
60-69 yrs < 4.5 ng/mL
70-79 yrs < 6.5 ng/mL

1.4.2 Sensitivity And Specificity Of PSA Testing And Role Of Free PSA In Determining Risk Of Cancer:
PSA testing sensitivity is approximately 67.5% to 80% (using 4.0 ng/mL as the upper limit of normal). If only PSA testing is used for screening, 20% to 30% of tumours will be missed. To improve sensitivity, a number of methods have been suggested, including: i) digital rectal exam (DRE) for early detection screening; ii) age-adjustment of PSA, using lower limits for younger men (see Section 1.4.1.1); and iii) PSA velocity (rate of PSA change) as a prompt for biopsy.

A PSA velocity of 0.75 ng/mL per year may indicate the presence of prostate cancer. These three methods increase the sensitivity of early detection, but also increase the number of prostate biopsies performed.

Improving the specificity of early detection should reduce the number of unnecessary biopsies. To improve specificity, other methods have been suggested, including: i) using higher PSA cut-off levels for men over 60 years old; ii) using percent-free-PSA levels; and iii) using PSA density. Prostate cancer patients have lower fractions of free PSA relative to total PSA measured. Men with elevated PSA levels, but with a ratio of free/total PSA >20% to 25% have significantly lower risk of prostate cancer found on biopsy.

References:
2. Berner A, Harvey S, Skjorten FJ. Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer. Br J Urol Int, 1999; 83 (1): 47-52
Part 2. Histology & Pathology

2.1 Histology
The vast majority of neoplasms of the prostate are adenocarcinomas. Occasionally, other histologies (sarcoma, transitional cell carcinoma, small cell carcinoma) may be seen. Prostate adenocarcinomas are typically graded by the Gleason score\(^1,2\); scores graded in the range 2-10. Tumours may also be divided as well differentiated (typically Gleason 2-6), moderately differentiated (Gleason 7), and poorly differentiated (Gleason 8-10). Tumour grade is a strong prognostic factor in both treated (surgery or radiation) patients as well as patients where observation is elected. To note, a Gleason score should not be assigned to biopsy specimen showing prostate cancer after the patient has been placed on androgen deprivation or finasteride (Propecia®, Proscar®).

2.2 Pathology
2.2.1 Pathologic Assessment of Prostate Biopsy:
The pathology report for needle biopsy specimens\(^3,4\) should include the following information:
- A comment concerning the adequacy of the specimen
- The presence or absence of malignancy
- The histologic type
- The histologic grade (Gleason Score)
- The presence or absence of perineural/lymphatic/vascular invasion
- Extension beyond the prostatic capsule into fat, if present
- Number of cores involved and percentage of surface area of cores submitted
- The presence of high grade Prostatic Intraepithelial Neoplasia (PIN), Atypical Small Acinar Proliferation (ASAP)

2.2.2 Pathological Assessment of TURP Specimens:
Reports on transurethrally resected specimens should include the information required when reporting needle biopsy specimens, and in addition should include the percentage of chips showing tumour.

2.2.3 Pathological Assessment of Radical Prostatectomy Specimen:
Radical prostatectomy specimen resection margins should be marked with ink and these should be sampled generously. Obvious tumours should be sampled and random sections of apparently normal prostatic tissue should be taken. Pathology reports should include the following information:
- AP, lateral, and apex to base dimensions of the prostate gland in centimeters
- The presence or absence of tumour
- The extent and location of tumour
- The histologic type
- Gleason patterns and score
- The presence of high grade PIN (prostatic intra-epithelial neoplasia)
- The presence or absence of vascular/lymphatic/perineural invasion
- The presence or absence of extraprostatic extension
- The status of the surgical margins (involved versus clear)
- Seminal vesicle invasion
- The presence or absence of nodal involvement, number of nodes examined, presence of extranodal extensions (if sampled)
### Table 2.1 Gleason Grading System For Prostatic Adenocarcinoma: Histologic Patterns

<table>
<thead>
<tr>
<th>Pattern</th>
<th>Peripheral Borders</th>
<th>Stromal Invasion</th>
<th>Appearance of Glands</th>
<th>Size of Glands</th>
<th>Architecture of Glands</th>
<th>Cytoplasm</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Circumscribed pushing expansile</td>
<td>Minimal</td>
<td>Simple, round, monotonously replicated</td>
<td>Medium, regular</td>
<td>Closely packed rounded masses</td>
<td>Similar to benign epithelium</td>
</tr>
<tr>
<td>2</td>
<td>Less circumscribed; early infiltration</td>
<td>Mild, with definite separation of glands by stroma</td>
<td>Simple, round, some variability in shape</td>
<td>Medium, less regular</td>
<td>Loosely packed rounded masses</td>
<td>Similar to benign epithelium</td>
</tr>
<tr>
<td>3A</td>
<td>Infiltration</td>
<td>Marked</td>
<td>Angular with variation in shape</td>
<td>Medium to large</td>
<td>Variable packed irregular masses</td>
<td>More basophilic than patterns 1 &amp; 2</td>
</tr>
<tr>
<td>3B</td>
<td>Infiltration</td>
<td>Marked</td>
<td>Angular with variation in shape</td>
<td>Small</td>
<td>Variable packed irregular masses</td>
<td>More basophilic than patterns 1 &amp; 2</td>
</tr>
<tr>
<td>3C</td>
<td>Smooth, rounded</td>
<td>Marked</td>
<td>Papillary and cribriform</td>
<td>Irregular</td>
<td>Round to elongate masses</td>
<td>More basophilic than patterns 1 &amp; 2</td>
</tr>
<tr>
<td>4A</td>
<td>Ragged infiltration</td>
<td>Marked</td>
<td>Microacinar, papillary and cribriform</td>
<td>Irregular</td>
<td>Fused with chains and cords</td>
<td>Dark</td>
</tr>
<tr>
<td>4B</td>
<td>Ragged infiltration</td>
<td>Marked</td>
<td>Microacinar, papillary and cribriform</td>
<td>Irregular</td>
<td>Fused with chains and cords</td>
<td>Clear (hypernephroid)</td>
</tr>
<tr>
<td>5A</td>
<td>Smooth, rounded</td>
<td>Marked</td>
<td>Comedocarcinoma</td>
<td>Irregular</td>
<td>Round to elongate masses</td>
<td>Variable</td>
</tr>
<tr>
<td>5B</td>
<td>Ragged infiltration</td>
<td>Marked</td>
<td>Difficult to identify gland lumens</td>
<td>Irregular</td>
<td>Fused sheets and masses</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Reprinted from: Table 7-3 from Bostwick DG: UROLOGIC SURGICAL PATHOLOGY, 1/e. p.360, © 1997 Mosby.
with permission from Elsevier
References:
Part 3. Diagnosis and Staging

3.1 Diagnosis- Prostate Biopsy:
An elevated PSA or abnormal DRE may indicate increased risk of prostate cancer, but they cannot determine a diagnosis of prostate cancer. The only method to confirm the presence of prostate cancer is a prostate biopsy. Usually, a prostate biopsy is performed transrectally with ultrasound guidance. Transrectal ultrasound (TRUS) has poor ability to diagnose prostate cancer, so a normal TRUS with abnormal DRE or elevated PSA should not be used as a criterion to avoid prostate biopsy. Prostate cancer is rarely diagnosed at the time of TURP.

3.1.1 Minimum Workup At The Time Of Prostatic Biopsy:
• Full history and physical examination, PSA blood test
• Bilateral biopsy of prostate with at least eight cores sampled. Additional samples may be taken from suspicious nodules or ultrasound abnormality, where appropriate

3.1.2 Indications For Re-Biopsy When No Invasive Cancer Present:
• Focus of ASAP or PIN (see 2.2.1) in a man eligible for curative therapy
• Progressively rising PSA
• Suspicious nodule

3.2 Staging Investigations
• Serum PSA will guide selection of staging studies for newly diagnosed prostate cancer
• Laboratory investigations: hemoglobin, liver function tests, creatinine, testosterone, alkaline phosphatase
• Consider bone scan, if PSA >10 ng/mL, or if Gleason Grade ≥ 7, if disease is locally advanced, or if there are symptoms suggestive of metastases (such as weight loss, bone pain)
• CT or MRI pelvic scans may be considered if a patient has an increased likelihood of lymph node metastases (>20%), a Gleason score ≥8, PSA > 20 ng/mL, T3 or T4 lesion.
• A pelvic lymph node dissection may be performed in very selected cases
### Table 3.2.1 T (Tumour) Definitions

<table>
<thead>
<tr>
<th>T</th>
<th>Clinical:</th>
<th>Pathologic (pT):</th>
</tr>
</thead>
<tbody>
<tr>
<td>T X</td>
<td>Primary tumour cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>T 0</td>
<td>No evidence of a primary tumour</td>
<td></td>
</tr>
<tr>
<td>T 1</td>
<td>Clinically inapparent tumour, neither palpable nor visible by imaging</td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td>Tumour incidental finding in 5% or less of tissue resected</td>
<td></td>
</tr>
<tr>
<td>T1b</td>
<td>Tumour incidental finding in more than 5% of tissue resected</td>
<td></td>
</tr>
<tr>
<td>T1c</td>
<td>Tumour identified by needle biopsy (e.g. because of elevated PSA)</td>
<td></td>
</tr>
<tr>
<td>T 2</td>
<td>Tumour confined within prostate (Note: tumour found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging is classified as T1c)</td>
<td></td>
</tr>
<tr>
<td>T2a</td>
<td>Tumour involves one-half of one lobe or less</td>
<td></td>
</tr>
<tr>
<td>T2b</td>
<td>Tumour involves more than one-half of one lobe, but not both lobes</td>
<td></td>
</tr>
<tr>
<td>T2c</td>
<td>Tumour involves both lobes</td>
<td></td>
</tr>
<tr>
<td>T 3</td>
<td>Tumour extends through prostate capsule (Note: invasion into the prostatic apex or into, but not beyond, the prostatic capsule is classified as T2)</td>
<td></td>
</tr>
<tr>
<td>T3a</td>
<td>Extracapsular extension (unilateral or bilateral)</td>
<td></td>
</tr>
<tr>
<td>T3b</td>
<td>Tumour invades seminal vesicle(s)</td>
<td></td>
</tr>
<tr>
<td>T 4</td>
<td>Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, rectum, levator muscles and/or pelvic wall</td>
<td></td>
</tr>
<tr>
<td>pT1</td>
<td>There is no pathologic T1 classification</td>
<td></td>
</tr>
<tr>
<td>pT2</td>
<td>Organ confined</td>
<td></td>
</tr>
<tr>
<td>pT2a</td>
<td>Unilateral, involving one-half of one lobe or less</td>
<td></td>
</tr>
<tr>
<td>pT2b</td>
<td>Unilateral, involving more than one-half of one lobe, but not both lobes</td>
<td></td>
</tr>
<tr>
<td>pT2c</td>
<td>Bilateral disease</td>
<td></td>
</tr>
<tr>
<td>pT3</td>
<td>Extraprostatic extension</td>
<td></td>
</tr>
<tr>
<td>pT3a</td>
<td>Extraprostatic extension (positive surgical margin indicated by an R1 descriptor- residual microscopic disease)</td>
<td></td>
</tr>
<tr>
<td>pT3b</td>
<td>Seminal vesicle invasion</td>
<td></td>
</tr>
<tr>
<td>pT4</td>
<td>Invasion of bladder, rectum</td>
<td></td>
</tr>
</tbody>
</table>

---

Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit www.cancerstaging.net.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.
### Table 3.2.2 N (Node) Definitions¹⁰

<table>
<thead>
<tr>
<th>N</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes were not assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No metastasis to regional lymph nodes</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis in regional lymph node(s)</td>
</tr>
</tbody>
</table>

### Table 3.2.3 M (Metastasis) Definitions¹⁰

<table>
<thead>
<tr>
<th>M</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX</td>
<td>Distant metastasis cannot be assessed (not evaluated by any modality)</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis present</td>
</tr>
<tr>
<td></td>
<td>M1a Non-regional lymph node(s)</td>
</tr>
<tr>
<td></td>
<td>M1b Bone(s)</td>
</tr>
<tr>
<td></td>
<td>M1c Other site(s) with or without bone disease</td>
</tr>
</tbody>
</table>

### Stage Groupings: TNM Subsets*¹⁰

<table>
<thead>
<tr>
<th>Stage</th>
<th>T1a</th>
<th>N0</th>
<th>M0</th>
<th>M1</th>
<th>G1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td></td>
<td>G2, 3-4</td>
</tr>
<tr>
<td></td>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
<td></td>
<td>Any G</td>
</tr>
<tr>
<td></td>
<td>T1c</td>
<td>N0</td>
<td>M0</td>
<td></td>
<td>Any G</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>Any G</td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>Any G</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
<th>T4</th>
<th>N0</th>
<th>M0</th>
<th>M1</th>
<th>Any G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N1</td>
<td>M0</td>
<td></td>
<td>Any G</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>Any NM1</td>
<td>M0</td>
<td>Any G</td>
<td></td>
</tr>
</tbody>
</table>

* Grading not generally used for staging at Capital District Health Authority

### References:

Part 4. Referral Information for the New Patient Visit

A letter of referral and a pathology report documenting the cancer diagnosis are the usual minimal requirements for a referral of adult patients to a tertiary cancer center. A referral need not be delayed due to incomplete results from tests (either due to test scheduling delays or waiting time for test results).

Local Urologist
• Refer as per usual practice within local community or health care district

Referral to the QEII Health Sciences Centre

Referrals to the Capital Health/QEII Cancer Care Program (CCP) may be faxed to the Referrals Office at 902-473-6079 (tel. 902-473-5140 or 902-473-6098). It is preferred that referrals be accompanied by the CCP Referral Form available upon request at the above phone numbers or available for downloading at www.cdha.nshealth.ca/physicianupdate. For urgent or emergent referrals, please page the appropriate specialist on call through the QEII HSC Locating service (902-473-2220) to discuss the referral.

Referral to the Cape Breton Cancer Centre

Referrals to the Cape Breton Cancer Centre may be directed to the referrals/booking office at 902-567-7774 (fax 902-567-7911). For urgent or emergent referrals, please page the appropriate specialist on call through the Cape Breton Regional Hospital Locating service (902-567-8000) to discuss the referral.

Referral Information

Letter of Referral*
A legible referral or consultation letter highlighting presenting signs, symptoms and pertinent findings

Laboratory Results*
a. Serum PSA (prostate specific antigen) levels- including old results*
b. CBC (complete blood counts)

Biopsy Reports*
a. Prostate biopsy reports
b. TURP biopsy reports

Operative Reports (relevant to the cancer)*
a. Prostatectomy
b. Orchiectomy
c. Other procedures

Diagnostic Imaging Reports*
a. Transrectal Ultrasound of prostate-reports*
b. Bone scans (with films) *
c. Any relevant chest radiographs (with films)
d. Any relevant CT scans
e. Any other relevant diagnostic imaging

Other Information
a. Any relevant consultation reports
b. Renal function test results (if done)
c. Relevant bloodwork: BUN, creatinine, calcium (if done)
d. Detailed information on any previous chemotherapy or radiotherapy of current malignancy
e. Any information on previous malignancies
f. Information on co-existing medical conditions and allergies

* Specific information which is necessary for proper triage of referrals

Please note: If the referring physician would like to discuss a case with a specialist, feel free to call the appropriate specialist (Radiation Oncology, Medical Oncology, or Urology, by calling 902-473-2222- ask for the specialist on call or a specific physician at this number). If any tests or reports are pending, the date of the procedure, and the location of the procedure should be noted, so that the reports may be obtained when available. Send in the referral while awaiting these results, to facilitate a timely appointment for your patient.
Part 5. Treatment

Note: For optimal patient care, psychosocial management is integrated with medical/surgical management of the disease and symptoms.

5.1 Curative Treatment Options By Risk Category:

Pretreatment PSA\(^1\)-\(^8\), grade\(^9\)-\(^13\) and clinical stage are prognostic factors for outcome following surgery\(^14\)-\(^16\), radiotherapy\(^17\)-\(^21\), expectant management\(^22\)-\(^25\) (See Appendix III for principles of expectant management) or observation\(^26\),\(^27\) (See Appendix IV for principles of observation) for non-metastatic disease. Various prognostic schemes combining different categories of these factors have been proposed\(^28\)-\(^31\) and, in general, these schemes stratify patients into low, intermediate and high risk categories. Low risk patients have a high chance of disease control with single modality therapy (or expectant management in selected patients); high risk patients have a high chance of systemic failure with localized treatment modalities and should be considered for adjuvant therapy. Treatment of intermediate risk patients is controversial.

5.2 Definition Of Risk Categories With Treatment Options\(^32\):

5.2.1 Low Risk

\[\text{T1-T2a and Low PSA (< 10ng/mL) and Low Gleason Grade (< 6)}\]

Treatment Options:

Patients may choose one of these options in discussion with their doctor\(^13\),\(^33\)

- Radical prostatectomy\(^14\),\(^16\),\(^34\)-\(^38\) (see Appendix V)
- External beam radiotherapy alone\(^38\)-\(^44\) (see Appendix VI - Comprehensive Version)
- Brachytherapy\(^45\)-\(^47\) (seed implant- see Appendix VI- Comprehensive Version)
- not available in Nova Scotia
- Expectant Management\(^22\),\(^48\)-\(^51\)
- Observation\(^13\),\(^52\)-\(^54\)

5.2.2 Intermediate Risk:

\[\begin{align*}
\text{T2b-T2c} \\
\text{or} \\
\text{PSA = 10-19 ng/mL} \\
\text{or} \\
\text{Gleason Grade = 7;}
\end{align*}\]

Treatment Options:

Patients may choose one of these options in discussion with their doctor\(^13\),\(^33\)

- Radical prostatectomy\(^14\),\(^16\),\(^25\),\(^35\)-\(^37\) with or without pelvic lymph node dissection (PLND)
- Neoadjuvant Androgen deprivation therapy (ADT- also known as hormonal therapy) (see Appendix VII- Comprehensive Version) and radical external beam radiotherapy\(^55\)
  - ADT given for 2-8 months prior to radiotherapy\(^56\)
  - ADT concurrent with radiotherapy may be given\(^55\)
- Dose-escalated conformal external beam radiotherapy (3D)\(^25\),\(^57\)
- ADT may be used as primary treatment if contraindication to radiotherapy and radical prostatectomy.
- Expectant Management\(^53\)
- Observation\(^13\),\(^34\),\(^53\),\(^58\)

5.2.3 High Risk:

\[\text{T3-T4 or Gleason Grade > 8 or PSA > 20ng/mL}\]

Treatment Options:

Patients may choose one of these options in discussion with their doctor\(^59\)

- Neoadjuvant ADT\(^25\),\(^55\),\(^56\),\(^60\)-\(^62\) and external beam radiotherapy (including elective treatment of pelvic...
lymph nodes\textsuperscript{63,64} (see Section 5.2.2) with or without 2-3 years of adjuvant ADT\textsuperscript{55,56,65-69}

- Radical prostatectomy\textsuperscript{70-73} – for highly selected patients with low volume disease; Not recommended for T3b-T4 patients
  - Post operative radiotherapy and/or ADT may be required
  - ADT may be used as primary treatment in very high risk patients with low chance of cure\textsuperscript{74-76}
  - Observation\textsuperscript{77}

5.3 Post-Prostatectomy Management

**Post-operative PSA Undetectable or PSA < 0.2mg/mL**

- pT2, pT0 NX,N0 M0 negative margin
  - Observation, standard follow-up management\textsuperscript{25}

- pT2 (positive margin), pT3a NX,N0 M0
  Options:
  - Radiation Therapy\textsuperscript{4,10,78-82} (+/- ADT)
  - Observation, standard follow-up management

- pT3b NX,N0 M0
  Options:
  - Radiation Therapy\textsuperscript{4,10,78-82} (+/- ADT)
  - ADT alone
  - Observation, standard follow-up management\textsuperscript{25}

- pT4 NX,N0 M0
  Options:
  - Radiation Therapy (+/- ADT)
  - ADT alone

- pTX N+ M0
  Options:
  - ADT\textsuperscript{25,83}
  - Observation, standard follow-up management

**Post-operative PSA Detectable**

PSA ≥ 0.2 ng/mL – See Salvage Therapy Section 5.4

5.4 Salvage therapy

5.4.1 Salvage Radiotherapy Post-Radical Prostatectomy\textsuperscript{25,79,81,84,85}

Should be considered in the setting of rising PSA (on at least two subsequent measurements) after radical prostatectomy (minimum PSA > 0.2 ng/dL) or first post-operative PSA > 0.2 ng/dL in patients who are more likely to have disease isolated to the prostatic bed.

Biochemical relapse-free survival (but not overall survival) is superior if radiotherapy initiated when PSA < 1 ng/dL, and PSA doubling time > 10 months, and PSA recurrence post-prostatectomy > 18 months

5.4.2 Salvage Therapy Post-Radiotherapy\textsuperscript{25}

In a highly selected subset of patients (e.g. low risk disease at diagnosis and long PSA doubling time and long disease-free interval) with three consecutive rises in PSA 3-4 months apart\textsuperscript{86} and PSA > 1.5 ng/mL, options may include:

- Prostatectomy
- Brachytherapy/seed implant
  - not available in Nova Scotia
- Cryotherapy
  - not available in Nova Scotia

5.5 Metastatic Cancer of the Prostate

Patients with metastatic or clinically detectable lymph node disease are considered to be incurable and are generally offered immediate ADT\textsuperscript{76,87}. This could include:

- LHRH agonist\textsuperscript{74,88-93}
- LHRH agonist plus antiandrogen\textsuperscript{92-94}
- Orchiectomy\textsuperscript{74,95,96}

Other patients who have extremely high-risk disease (without proven distant disease) who are unlikely to be cured and/or those who have significant co-morbid disease may be considered for immediate or delayed ADT alone\textsuperscript{55}.
5.6 Hormone Refractory Prostate Cancer

Hormone refractory prostate cancer is defined by rising PSA, worsening radiographic disease, or worsening symptoms while on ADT. Castrate testosterone levels should be confirmed (< 1.75 nmol/L) and effective ADT implemented if not the case.

Secondary hormonal manipulations may be indicated. These may include:
- Addition of antiandrogen agent to orchiectomy or LHRH agonist92-94 (See Appendix VII- Comprehensive Version)
- Discontinuation of antiandrogen if patient has been receiving one97-100
- Other less commonly-used manipulations101 (See Appendix VII- Comprehensive Version)

Symptom control should be optimized, especially analgesic therapy and supportive measures. The palliative care team should be consulted. Other interventions aimed at improving symptom control may include:
- Urological intervention (e.g. TURP)
- Radiotherapy (localized or hemi-body)102
- Low dose steroids103 (i.e., prednisone 5-10 mg/day or dexamethasone 1-2 mg/day)
- Systemic radionuclides104-106 (See Appendix X- Comprehensive Version)
- Palliative chemotherapy (See Appendix VIII- Comprehensive Version)
- Docetaxel plus prednisone106-107 (See Appendix IX- Comprehensive Version)
- Mitoxantrone plus prednisone108
- Bisphosphonate therapy
- Data is emerging to indicate zoledronic acid decreases skeletal events (e.g. pathologic fractures, need for radiotherapy, need for surgery, spinal cord compression) and decreases pain in hormone refractory prostate cancer109.

References:


80. Carter GE, Lieskovsky G, Skinner DG et al.: Results of local and/or systemic adjuvant therapy in the management of pathological stage C or D1 prostate cancer following radical prostatectomy. J Urol, 1989; 142 (5): 1266-70; discussion 1270-1.


Part 6. Follow-up

6.1 Follow-up after Curative Therapy
The goal of follow up after curative therapy is to detect recurrence and to monitor for side effects from the treatment. In addition, follow up visits should include reassessment and management of any supportive care issues, including psychosocial, sexual and/or incontinence problems. The follow up schedule after curative radiotherapy or radical prostatectomy will depend on a number of factors, including the initial clinical or pathological stage of the disease, acute or chronic toxicities, the post therapy PSA levels, or rising PSA levels. The following schedules are recommended after each of these curative treatments. The physician should review the follow up schedule with each patient before completion of initial treatment, so that the patient has an understanding of what to expect.

6.1.1 Follow-up after Curative Radiotherapy

<table>
<thead>
<tr>
<th>Year</th>
<th>Frequency</th>
<th>Provider</th>
<th>Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5</td>
<td>every 6-24 months</td>
<td>RO</td>
<td>Clinical assessment, DRE</td>
</tr>
<tr>
<td>1-5</td>
<td>every 3-4 months</td>
<td>RO</td>
<td>PSA *</td>
</tr>
<tr>
<td>&gt;5</td>
<td>every 1-3 years</td>
<td>RO</td>
<td>Clinical assessment, DRE</td>
</tr>
<tr>
<td>&gt;5</td>
<td>every 3-6 months</td>
<td>RO</td>
<td>PSA</td>
</tr>
</tbody>
</table>

* Serum testosterone may be monitored in patients receiving ADT

RO: radiation oncologist, for follow-up of treatment effectiveness and long-term toxicity
DRE: digital rectal examination
PSA: prostate specific antigen

6.1.2 Follow-up after Curative Radical Prostatectomy

<table>
<thead>
<tr>
<th>Year</th>
<th>Frequency</th>
<th>Provider</th>
<th>Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3</td>
<td>every 3-12 months</td>
<td>U</td>
<td>PSA, Clinical assessment</td>
</tr>
<tr>
<td>3-</td>
<td>every 6-12 months</td>
<td>U</td>
<td>PSA, Clinical assessment</td>
</tr>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

U: urologist
PSA: prostate specific antigen

6.2 Follow-up for patients with Metastatic Disease
The interval, investigations, and providers will be determined by the patient’s clinical condition and symptoms.

References:
1. National Comprehensive Cancer Network
   Practice Guidelines in Oncology, Prostate Cancer
   v.1.2005. NCCN, 2005
Part 7. Supportive Care Issues

7.1 Psychosocial Needs
Prostate cancer patients, like all cancer patients, may have a number of supportive care needs, often including the need for psychosocial support. The psychosocial needs will differ from newly diagnosed men, to those living with the cancer, and to those who fail treatment.

Psychosocial support may be needed for help to cope with the cancer experience. For some patients, mental health support may be needed. There is about 25% chance of clinically significant depression, anxiety and adjustment difficulties. In addition, one must also pay attention to the impact of the cancer on the patient’s partner. Prostate cancer and its treatment may cause or exacerbate erectile dysfunction, urinary incontinence, a change in mood and sleep patterns. It is the responsibility of the attending health caregivers to provide basic support through the continuum of disease. This should include basic screening for signs of depression in the patient. Where available, cancer patient navigators are a valuable resource for patients. There may be peer support groups in local communities to help patients.

Screening for distress (see Section 8.12) should be included in patient visits at diagnosis and other key transition points (e.g. six months after treatment completion, disease recurrence, progression to advanced disease). For high risk patients, distress screening should be included at each visit. Risk factors to consider in selecting the frequency of distress screening include:
- age < 60
- mental health history
- social isolation
- receiving ADT (hormone therapy)
- greater burden of illness

If possible, partners should be involved in the process of screening for distress.

If there are specific needs beyond the abilities of the front-line caregivers, a referral to the Psychosocial Oncology Team at either of the Cancer Centres, or an appropriate local resource (e.g. mental health specialists), may be considered. Specialized psychosocial support may be offered by psychosocial counsellors, psychologists, psychiatrists, social workers, clinical nurse specialists, or other trained professionals.

7.2 Symptom Management
The treatment of prostate cancer is complex and may include surgery, external beam radiotherapy, brachytherapy, ADT, or chemotherapy. These treatments have specific and overlapping side effects, which may affect quality of life. Common side effects include erectile dysfunction, urinary incontinence, loss of libido, hot flashes, and mood swings.

7.2.1 Erectile Dysfunction and Sexual Health
Following prostate cancer treatment, there is a high incidence of erectile dysfunction (ED), up to 85% depending on the treatment. Prior to treatment, 30-40% of men report pre-existing ED as a result of other factors. Therefore, it is important to assess sexual issues prior to treatment, to determine baseline and to identify the degree of concern for the patient and his partner. This assessment can identify many issues beyond baseline ED. It is recommended that the man’s partner should be allowed to participate in the pre-treatment assessment. (Query their
current level of sexual activity, how satisfied they are with this and how concerned they are about possible changes.) If necessary, consider initiation of sexual counselling to address aspects of the couple’s relationship. Following radical prostatectomy or radical radiotherapy, at 6-12 weeks post-treatment, a visit should be planned to discuss possible resumption of sexual activity (including issues such as the return of erections, morning fullness). At this time, consideration may be given to initiate oral therapy with a phosphodiesterase enzyme inhibitor (e.g. sildenafil [Viagra®], tadalafil [Cialis®], vardenafil [Levitra®]) to stimulate erectile tissue. It is important to note with the patients that the purpose of these oral agents is to preserve tissue and enhance penile health, not necessarily for sexual relations.

A follow-up visit should be planned for 3-12 months after treatment to discuss the couple’s sexual function and satisfaction. If the oral agent is not working, consider prostaglandin injections (e.g. alprostadil [Caverject®]) and a referral to erectile dysfunction (ED) clinic (Note: only available in Halifax). Another option could be referral for couples counselling or sex therapy, where available. This should be re-assessed at 12 months, or as necessary.

7.2.2 Urinary Incontinence
Urinary incontinence is another common consequence of prostate cancer treatment. About 2-3 weeks after surgery, the catheter is usually removed. Upon removal of the catheter, patients should be able to demonstrate Kegel exercises. There should also be a discussion with the patient about incontinence. Patients often need reassurance that this is expected, and they may need information on different incontinence products.

At three months after treatment, a follow-up visit should be planned to discuss how the patient is doing with incontinence. If possible, a referral for urodynamic assessment (where available) may be considered to assess options for biofeedback training to help the patient regain control.

If the patient is still having trouble with incontinence problems at 12 months post-treatment, consider referral for an incontinence device (a pump that is inserted during day surgery).

7.2.3 Loss of Libido, Hot Flashes, Mood Swings
These symptoms are caused by testosterone reduction and occur during hormonal treatment, and possibly for months to years afterwards. Supportive care and or medications (see Appendix VII) may be considered.

7.2.4 Proctitis
Chronic irritation of the lower rectum occurs in about 10% percentage of prostate cancer patients treated with external radiation. The symptom of mild rectal bleeding usually develops within 6-12 months after radiation, due to vessel telangiectasia. It may last for years, usually improving with time. Proctitis may also cause discomfort during defecation or rectal urgency.

Any patient with persistent rectal bleeding needs full assessment including...
colonoscopy by a gastroenterologist or surgeon. Once confirmed, radiation-induced proctitis can be treated symptomatically by modifying diet (to ensure avoidance of constipation) and with medications or procedures, listed below.

For patients with clinically significant symptoms of proctitis (rectal urgency, tenesmus, pain with bowel movements) treatment with either Anusol®- HC (Hydrocortisone Acetate – Zinc Sulfate) suppositories 1 PR q8h prn or Proctosone® or Proctosedyl® (Hydrocortisone Acetate – Framycetin Sulfate – Cinchocaine HCL – Esculin) suppositories 1 PR q8h prn, is recommended. If these do not provide adequate relief, Proctofoam™- HC (Hydrocortisone Acetate – Pramoxine HCL), Anugesic® - HC (Pramoxine HCL – Hydrocortisone Acetate – Zinc Sulfate), Xylocaine® (Lidocaine HCL) jelly 2%, all given PR q8h prn, or oral analgesics can be prescribed, in severe cases.

For bleeding occurring more than one year after radiation treatment, mesalamine (Salofalk®, Rowasa®) suppositories 1000mg PR for two weeks, repeated on a monthly basis, can be helpful. Occasionally, local therapy such as laser treatment is required for refractory bleeding requiring transfusion. Hyperbaric oxygen can also be helpful for recurrent bleeding. If life-threatening bleeding occurs, instillation of Formalin has also been shown to be effective to stop bleeding. In cases of complete, persistent incontinence, severe refractory rectal pain or fistula, defunctioning colostomy should be considered.

### 7.3 Other Resources

Some prostate cancer patients may benefit from involvement of the local palliative care service, for advanced symptom management expertise and end of life care when appropriate.

Referral to palliative care is available across the province, as illustrated in Figure 8.13.

Guidelines for the management of symptoms are under development by the CCNS Supportive Care Cancer Site Team. As these guidelines are completed, they are posted on the Cancer Care Nova Scotia website (www.cancercare.ns.ca). Current CCNS symptom management guidelines are:


**References:**

Part 8. Practice Pathways

8.1 Diagnosis and Referral of Prostate Cancer - Overview

Suspicion of Prostate Cancer:
- Elevated PSA and/or abnormal DRE (See Appendix II for Position Statement on Early Detection of Prostate Cancer)
- Symptoms which led to PSA/DRE
- Identified by Primary Care Physician

Referral to Urologist

Prostate biopsy
- Biopsy sample to Pathology Lab

Invasive Cancer Present

Staging Investigations
- Serum PSA levels
- Consider bone scan (if PSA >10 ng/mL or if Gleason Grade > 7, if disease is locally advanced, or if there are symptoms suggestive of metastases)
- CT or MRI pelvic scans, if PSA > 20 ng/mL
- Pelvic lymph node dissection, if PSA > 20 ng/mL, or if PSA > 10mg/L and Gleason Grade > 7

Management by Risk Category

Referral to Cancer Centre if Radiotherapy and/or Chemotherapy under consideration

Patient should be given patient education materials (‘Reef Knot’ package or equivalent) on diagnosis by urologist
- to assist with access to community services and peer support
- patient education materials
- Nova Scotia ‘Reef Knot’ program- call CCNS for details

No Invasive Cancer Present

Continue to follow PSA levels (by Urologist or Family Physician) +/- biopsies

Assess current sexual function and discuss potential impact of treatment options (e.g. sexual dysfunction, incontinence) and impact on patients and partners

Referral Information:
A letter of referral is the minimal requirement for a referral. A referral need not be delayed due to delays in scheduling tests or delayed reporting of tests

Local Urologist
- Refer as per usual practice within local community or health care district

QEI Health Sciences Centre:
- Faxed referrals to the QEII Cancer Care Program (CCP) Referrals Office at 902-473-6079 (tel. 902-473-5140 or 902-473-6098). It is preferred that referrals be accompanied by the CCP Referral form available upon request at the above phone numbers or available for downloading at www.cdha.nshealth.ca/physicianupdate

Cape Breton Cancer Centre:
- Direct referrals to the Referrals/Booking office at 902-567-7774 (fax 902-567-7911)

Urgent Referrals:
- For urgent or emergent referrals, in Halifax- page the appropriate specialist on call through the Locating service (902-473-2220); in Cape Breton- page the appropriate specialist on call through the Locating service (902-567-8000)

Referral Information:
- Letter of Referral*
- Laboratory Results*- CBC, PSA (including old results)
- Biopsy Pathology Reports
- Operative Reports (prostatectomy, orchietomy, other)
- Diagnostic Imaging Reports (TURP, bone scans, chest X-ray, CT scans, other)
- Specific information which is necessary for proper triage of referrals

* Specific information which is necessary for proper triage of referrals
### 8.2 Initial Treatment Options for Prostate Cancer

**Low Risk:**
- T1-T2a
- Low PSA (<10 ng/mL)
- Low Gleason Grade (≤6)

- **Prostatectomy**
- **External beam radiotherapy alone**
- **Brachytherapy (seed implant - not available in NS)**
- **Expectant Management**
- **Observation**

**Intermediate Risk:**
- T2b-T2c
- PSA = 10-20 ng/mL
- Gleason Grade = 7

- **Prostatectomy**
- **ADT as primary treatment if contraindication to radiotherapy and prostatectomy**
- **Expectant Management**
- **Observation (for patients with significant morbidity or poor life expectancy)**

- **Dose-escalated conformal external beam (3D) radiotherapy**

**High Risk:**
- T3-T4
- Gleason Grade ≥8
- PSA >20 ng/mL

- **Prostatectomy (for highly selected patients with low volume disease; NOT RECOMMENDED for T3b-T4 patients)**
- **Post operative radiotherapy and/or ADT may be required**
- **ADT as primary treatment in very high risk patients with low chance of cure**
- **Observation (for patients with significant morbidity or poor life expectancy)**

### 8.3 Observation

- Observation consists of medical follow up where it is unlikely that the patient will be treated with radiation therapy or surgery for cure due to a limited life expectancy or severe medical co-morbidities. Treatment at symptomatic progression will likely consist of ADT with additional interventions given with the intent of improving impairments in prostate cancer-specific health-related quality of life.
8.4 Expectant Management

- Expectant management involves actively monitoring the course of disease with the expectation to intervene if the cancer progresses or if symptoms become imminent.
- Patients with clinically localized cancers that are candidates for definitive treatment and choose expectant management should have regular follow up.
- DRE and PSA every six months.
- Needle biopsy of the prostate may be repeated within 6 mo of diagnosis if initial biopsy was < 10 cores or assessment discordant (e.g., palpable tumour contralateral to side of positive biopsy).
- Needle biopsy should be performed within 18 months if > 10 cores obtained initially, then periodically.
- A repeat biopsy may be indicated for any sign of disease progression by exam or markers.

8.5 ADT (Androgen Deprivation Therapy - Hormonal Regimens)

The choice of initial orchiectomy or androgen deprivation (hormonal) agent(s) for any individual patient will depend on many factors.
- Combined Androgen Blockade (CAB- LHRH agonist plus non-steroidal antiandrogen agent) is not routinely indicated.
- Monotherapy with nonsteroidal antiandrogens is not routinely indicated.
- After initial failure of ADT, secondary hormonal manipulation should be tried (e.g., addition of a non-steroidal antiandrogen or discontinuation of non-steroidal antiandrogen if already on).
- Other hormonal manipulations, such as ketoconazole or estrogens may be tried. Some phase II trials show a decline in PSA. There are no randomized data to support any survival advantage.

OPTIONS:

1. **Orchiectomy**
   - The testicles are surgically removed. The procedure is done as an outpatient, usually done under local anesthetic. Surgical castration (orchiectomy) is permanent.

2. **LHRH Agonists**
   - **Goserilin (Zoladex®)** 3.6 mg SC Depot q28d OR 10.8 mg SC Depot q84d
   - **Leuprolide (Lupron®-IM, Eligard®-SC)** 7.5 mg q28d OR 22.5 mg q84d (3mo) IM/SC Depot OR 30 mg q112d (4 mo)/ 45 mg q168d (6mo) SC Depot
   - **Buserilin (Suprefact®)** 6.3 mg SC Depot q56d OR 9.45 mg IM Depot q120d
   - **Note:** Due to an initial rise in testosterone levels, patients should be given a non-steroidal antiandrogen (see below) for 2-4 weeks at the same time as their first LHRH agonist dose.

3. **Non-steroidal Antiandrogen Agents**
   - **Flutamide (Euflex®)** 250 mg PO TID
   - **Bicalutamide (Casodex®)** 50 mg PO daily, up to 150 mg PO daily to TID
   - **Nilutamide (Anandron®)** 50 mg PO BID or TID

4. **Other Hormonal Treatments**
   - **Cyproterone (Androcur®)** 50-100 mg PO BID or TID
   - **Megestrol (Megace®)** 80-160 mg PO daily
   - **Ketoconazole (Nizoral®)** 400 mg PO TID (+/- Hydrocortisone 20 mg qAM & 10 mg qPM)
   - **Estrogens- e.g. Diethylstilbestrol** 1 mg PO Daily
8.6 Post-Prostatectomy Management

Post-operative PSA Undetectable or PSA < 0.2 ng/mL

- pT2, pT0 NX,N0 M0
  - Negative margin
  - No therapeutic interventions, standard follow-up management

- pT2 (positive margin), pT3a NX,N0 M0
  - Radiation Therapy (+/- ADT)

- pT3b NX,N0 M0
  - Radiation Therapy (+/- ADT)
  - No therapeutic interventions, standard follow-up management
  - Radiation Therapy (+/- ADT)

- pT4 NX,N0 M0
  - Radiation Therapy (+/- ADT)
  - ADT alone
  - ADT alone
  - ADT alone

- pTX N+ M0
  - No therapeutic interventions, standard follow-up management

Assess effect of treatment(s) on patient function (esp. incontinence & sexual dysfunction) and psychosocial distress. Manage symptom(s) and distress as appropriate

Post-operative PSA Detectable PSA ≥ 0.2 ng/mL

- See Salvage Therapy

8.7 Salvage Therapy

Post-Prostatectomy
Rising PSA or first post-operative PSA > 0.2 ng/mL

- Radiotherapy
- No therapeutic intervention

Post-Radiotherapy
Selected subset of patients (e.g. low risk disease at diagnosis and long PSA doubling time and long disease-free interval) with three consecutive rises in PSA 3-4 months apart and PSA > 1.5 ng/mL

- Prostatectomy
- Brachytherapy (seed implant- not available in NS)
- Cryotherapy (not available in NS)
- No therapeutic intervention
8.8 Metastatic and Incurable Prostate Cancer

Metastatic cancer or clinically detectable lymph node disease

Immediate ADT

Delayed ADT

High-risk disease (without proven metastases)
- unlikely to be cured and/or
- significant co-morbid disease

Immediate or delayed ADT

Consider referral to Palliative Care service (see page 29) and/or provincial home care service

8.9 Hormone Refractory Prostate Cancer

Prostate cancer managed with ADT
- Rising PSA and/or
- Worsening radiographic disease and/or
- Worsening symptoms

Castrate Testosterone Level

Yes

Secondary Hormonal Treatment

Addition of anti-androgen agent to LHRH agonist or orchiectomy

Discontinuation of anti-androgen (if already on one)

Other Hormonal Treatment:
- Cyproterone
- Ketoconazole
- Megestrol
- Estrogen

Optimize analgesic therapy for pain management (see CCNS Guidelines for Management of Cancer-Related Pain)

Urological intervention (e.g. TURP)

Radiotherapy (localized or hemi-body)

Low dose steroids
- (e.g. prednisone 5-10 mg/day or dexamethasone 1-2 mg/day)

Systemic radionuclides (e.g. Strontium 89)
- See Comprehensive Version Appendix X

Chemotherapy (docetaxel plus prednisone or mitoxantrone plus prednisone)

Bisphosphonate therapy
- (e.g. zoledronic acid 4 mg IV)
8.10 Management of Sexual Dysfunction

Pre-treatment assessment for normal sexual function

Initiate post-operative/post-treatment discussions (6-12 weeks after treatment):
- Consider institution of oral agents (sildenafil (Viagra®), tadalafil (Cialis®), vardenafil (Levitra®)) to conserve penile health
- Urologist/radiation oncologist

At 3-12 months post-treatment:
- Assess efficacy of oral agents and need for sexual function
- If ineffective, consider penile injection therapy
- Erectile Dysfunction clinic or urologist/radiation oncologist
- Consider couple counselling as appropriate

Reassess at 12 months:
- Sexual function, distress issues

8.11 Management of Incontinence

Pre-treatment visit:
- Assessment of bladder function
- Instruction on Kegel exercises
- Training on incontinence products
- Discussion with patient about incontinence

2-3 weeks postop (at time of catheter removal):
- Discussion with patient about incontinence
- Patient demonstration of Kegel exercises

Three months post treatment:
- Discussion with patient about any incontinence
- Referral for Urodynamic studies, if necessary

One year post treatment:
- Reassess level of continence, consider incontinence device if necessary

See Management of Psychosocial Issues (8.12)
8.12 Management of Psychosocial Issues

Screening and intervention should include both the patient and his partner

Risk factors for psychosocial distress (e.g. depression, anxiety, adjustment disorders) in prostate cancer

Low Risk

Periodic screening at diagnosis, six months after treatment completion, disease recurrence, progression to advanced disease

High Risk

Routine screening at each visit through disease continuum

Referral as appropriate for identified psychosocial distress problem(s)

Risk factors for distress:
- age < 60
- mental health history
- social isolation
- receiving ADT
- high burden of illness
- advanced stage of cancer
- unresolved urinary incontinence
- high sexual dissatisfaction
- multiple life stressors

8.13 Management of Pain and Other Symptoms

Referral of a cancer patient who needs help with pain or symptom management, or for palliative care

To The Attending Oncology Team:
- See page 23

To The Cancer Patient Navigator:
- 1-866-524-1234 from anywhere in Nova Scotia

To The District Palliative Care/Supportive Care Service:
- South Shore Health: 902-634-7369 or 902-354-3436
- South West Health: 902-742-3542 Ext. 414
- Annapolis Valley Health: 902-678-7381 Ext. 2270
- Colchester East Hants Health Authority: 902-893-5554 Ext. 2306
- Cumberland Health Authority: 902-667-5400 Ext. 6373
- Pictou County Health: 902-752-7600 Ext. 4190
- Guysborough Antigonish Strait Health Authority: 902-867-4296 or 902-867-4436
- Cape Breton District Health Authority: 902-567-7846
- Capital Health Cancer Care Program: 902-473-3119